Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474777 | 0.86 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL17754512 | 0.86 | — | — | |
| SCHEMBL19566535 | 0.86 | — | — | |
| SCHEMBL21202645 | 0.86 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL17754490 | 0.86 | — | — | |
| SCHEMBL17754508 | 0.84 | — | — | |
| SCHEMBL17754496 | 0.84 | SMPD1 (0.34) | SMPD1 | |
| SCHEMBL8928340 | 0.84 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL18892768 | 0.84 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL8752635 | 0.84 | SMPD1 (0.30) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20160138029-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20160138029-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | SMPD1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.